“We will continue to pursue legal action against those who provide potentially unsafe and ineffective compounded ‘semaglutide’ products and knowingly deceive patients who are seeking treatment, thereby eroding public trust in the safety of FDA-approved medicines,” said Doug Langa, executive vice president, North America operations and president of Novo Nordisk.
Novo Nordisk filed a flurry of lawsuits across the country last week claiming various entities, including weight loss clinics and medical spas, violated its trademark and falsely advertised its semaglutide products, Ozempic, Wegovy and Rybelsus.
The pharmaceutical company filed nine lawsuits accusing the defendants of misappropriating its marks to sell semaglutide-based compounded drugs for weight loss without approval from the U.S. Food and Drug Administration. Nearly half of the cases were filed in Florida with the company also filing suit in Tennessee, Montana, Colorado, Illinois and Texas.
